MedPath

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for Breast Cancer Trial Enrollment

• PredicineCARE™ liquid biopsy assay enabled the identification and enrollment of PIK3CA-positive patients in a Phase III breast cancer trial in China. • The PI3Kα inhibitor-based regimen demonstrated a doubling of progression-free survival, offering significant hope for breast cancer patients with PIK3CA mutations. • PredicineCARE™ is a next-generation sequencing (NGS) assay that facilitates blood-based testing to detect genomic alterations and has received FDA breakthrough device designation and New York State approval.

Predicine's PredicineCARE™ liquid biopsy assay has been highlighted in The New England Journal of Medicine (NEJM) for its role in identifying and enrolling PIK3CA-positive patients in a Phase III breast cancer trial conducted in China. The assay facilitated the selection of patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer (mBC) for the trial.

Clinical Impact of PI3Kα Inhibition

The study demonstrated that the PI3Kα inhibitor-based regimen led to a doubling of progression-free survival (PFS) in the selected patient population. Dr. Huiping Li, Chair of the Department of Breast Oncology at Peking University Cancer Hospital & Institute, emphasized the significance of biomarker testing in identifying patients who benefit from this new first-line standard of care.

PredicineCARE™ Assay Details

PredicineCARE™ is a next-generation sequencing (NGS) assay designed for blood-based detection of genomic alterations. It has received FDA breakthrough device designation and New York State approval, underscoring its potential clinical utility in personalized cancer care.

Company Perspective

Dr. Shidong Jia, Founder & CEO of Predicine, stated that the publication in NEJM demonstrates the assay's value in global clinical trials and personalized cancer care. He highlighted the company's commitment to providing robust, efficient, and cost-effective early biomarker testing to identify patients who may benefit from targeted therapy.

About Predicine

Predicine is a global molecular insights company focused on advancing precision medicine in oncology and infectious disease diagnostics. The company develops technologies for cell-free DNA and cell-free RNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response monitoring, minimal residual disease monitoring, and disease progression. Predicine offers blood, urine, and tissue-based NGS assays for clinical trials, companion diagnostic (CDx) development, and commercialization.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BeiGene Announces Positive Phase 3 Trial Results for Tislelizumab in Nasopharyngeal Cancer

BeiGene has revealed promising results from its Phase 3 trial of tislelizumab combined with chemotherapy for treating recurrent or metastatic nasopharyngeal cancer, showing significant progression-free survival benefits. The findings were presented at the ESMO Immuno-Oncology Congress 2021, with a supplemental biologics license application currently under review in China.

Pimicotinib Shows Positive Phase 3 Results in Tenosynovial Giant Cell Tumors

Pimicotinib demonstrated a 54% objective response rate at week 25, significantly higher than the 3.2% observed in the placebo group in TGCT patients.
The MANEUVER trial confirmed pimicotinib's potential as a new treatment option by showing statistically significant improvements in patient outcomes, including reduced stiffness and pain.

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for PIK3CA-Mutated Breast Cancer Trial

PredicineCARE™ liquid biopsy assay identified and enrolled patients with PIK3CA-mutated metastatic breast cancer in a Phase III trial in China, as published in NEJM.
The PI3Kα inhibitor-based regimen doubled progression-free survival, showing consistent benefits across patient subgroups with the aid of PredicineCARE™ biomarker testing.

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for Breast Cancer Trial Enrollment

PredicineCARE™ liquid biopsy assay facilitated the identification and enrollment of patients with PIK3CA-mutated metastatic breast cancer in a Phase III trial.
The PI3Kα inhibitor-based regimen in the trial doubled progression-free survival, showing consistent benefits across patient subgroups.

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for Breast Cancer Trial Enrollment

PredicineCARE™ liquid biopsy assay facilitated the identification and enrollment of PIK3CA-positive patients in a Phase III breast cancer trial in China, as published in _The New England Journal of Medicine_.
The PI3Kα inhibitor-based regimen demonstrated a doubling of progression-free survival, offering significant hope for breast cancer patients with PIK3CA mutations.

NEJM Highlights PredicineCARE™ Liquid Biopsy Role in Roche's Itovebi Breast Cancer Trial

PredicineCARE™ liquid biopsy assay was pivotal in Roche's INAVO120 Phase 3 trial, identifying PIK3CA-mutated metastatic breast cancer patients.
The assay's use contributed to the FDA approval of Inavolisib (Itovebi) as a first-line treatment for HR+, HER2-negative breast cancer with PIK3CA mutations.

NEJM Highlights PredicineCARE™ Liquid Biopsy Assay in Roche's Phase III Trial

Roche's Phase III trial utilizes PredicineCARE™ liquid biopsy assay for patient selection and monitoring, showcasing its pivotal role in clinical research.
The assay's ability to detect actionable genomic alterations in plasma ctDNA guides targeted therapy decisions, potentially improving patient outcomes.

PredicineCARE Liquid Biopsy Validated in Roche's Phase III INAVO120 Breast Cancer Trial Published in NEJM

PredicineCARE's liquid biopsy assay was pivotal in Roche's INAVO120 Phase 3 trial, identifying PIK3CA-mutated metastatic breast cancer patients for Inavolisib treatment.
The FDA approved the Itovebi-based regimen as a first-line treatment for HR+, HER2-negative breast cancer with PIK3CA mutations, partly due to PredicineCARE's role.

Genentech's Itovebi Combo Demonstrates Overall Survival Benefit in HER2-Negative Breast Cancer

Genentech's Itovebi, combined with palbociclib and fulvestrant, significantly improved overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
The Phase III INAVO120 trial showed a 57% reduction in the risk of disease progression or death compared to palbociclib and fulvestrant alone.

Genentech's Itovebi Demonstrates Significant Overall Survival Benefit in PIK3CA-Mutated Breast Cancer

Genentech's INAVO120 study showed Itovebi, combined with palbociclib and fulvestrant, significantly improved overall survival (OS) in patients with PIK3CA-mutated, HR-positive, HER2-negative metastatic breast cancer.
The Itovebi-based regimen reduced the risk of disease worsening or death by 57% compared to palbociclib and fulvestrant alone, building upon previously reported progression-free survival benefits.

Reference News

[1]
UPDATE: PredicineCARE™ Liquid Biopsy Assay Featured in NEJM - GlobeNewswire
globenewswire.com · Nov 6, 2024

Predicine's PredicineCARE™ liquid biopsy assay, published in NEJM, identifies PIK3CA-positive patients in China, showing...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy